Iceland· IS-EU/1/14/929/001-003
Revinty Ellipta
A vilanterol und fluticason furoat product containing fluticasonum inn fúróat,vilanterolum inn trífenatat, registered in Iceland by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 11 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Vilanterol und fluticason furoat is registered in 11 of 19 countries.
Countries holding a registration under ATC R03AK10 (vilanterol und fluticason furoat), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Vilanterol und fluticason furoat · ATC R03AK10
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of vilanterol und fluticason furoat costs, country by country.
Normalised to the WHO defined daily dose (25 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Vilanterol und fluticason furoat · price per daily dose (25 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$0.30
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Fluticasonum INN fúróat,Vilanterolum INN trífenatat
- Manufacturer
- GlaxoSmithKline Trading Services Limited
- Country
- Iceland (IS)
- ATC code
- R03AK10
- ATC class
- Vilanterol und Fluticason furoat
- Defined daily dose
- 25 mcg, Inhal
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
1 interaction on record for vilanterol und fluticason furoat.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vilanterol und fluticason furoat · interactions on record
1 record
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to checkSame class
Other records under R03AK10
Vilanterol und fluticason furoat, as other registers publish it.
- CanadaBREO ELLIPTAGLAXOSMITHKLINE INC
- CanadaBREO ELLIPTAGLAXOSMITHKLINE INC
- FinlandRelvar ElliptaOrifarm Oy
- FinlandRelvar ElliptaGlaxosmithkline Trading Services Limited
- FinlandRelvar ElliptaGlaxosmithkline Trading Services Limited
- FinlandRelvar Ellipta2care4 ApS
- FinlandRelvar ElliptaParanova Oy
- NorwayRelvar ElliptaGlaxoSmithKline Trading Services Limited
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e0c6a5ec-c36e-4f8e-ad97-8ef184048216 GET /v1/drugs/e0c6a5ec-c36e-4f8e-ad97-8ef184048216?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innöndunarduft, afmældir skammtar",
"source": "lyfjastofnun",
"atc_raw": "R03AK10",
"marketed": false,
"strength": "92 míkróg/22 míkróg",
"ma_number": "EU/1/14/929/001-003",
"substance": "Fluticasonum INN fúróat,Vilanterolum INN trífenatat",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt",
"ma_issued_serial": "41761"
}See everything about vilanterol und fluticason furoat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.